Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates.

Roth JC, Cassady KA, Cody JJ, Parker JN, Price KH, Coleman JM, Peggins JO, Noker PE, Powers NW, Grimes SD, Carroll SL, Gillespie GY, Whitley RJ, Markert JM.

Hum Gene Ther Clin Dev. 2014 Mar;25(1):16-27. doi: 10.1089/humc.2013.201.

2.

Evaluation of the Safety and Biodistribution of M032, an Attenuated HSV-1 Virus Expressing hIL-12, After Intracerebral Administration to Aotus Non-Human Primates.

Roth JC, Cassady KA, Cody JJ, Parker JN, Price KH, Coleman JM, Peggins JO, Noker PE, Powers N, Grimes S, Carroll SL, Gillespie GY, Whitley R, Markert J.

Hum Gene Ther Clin Dev. 2014 Feb 28. [Epub ahead of print]

PMID:
24579875
3.

Evaluation of hepatic and thyroid responses in male Sprague Dawley rats for up to eighty-four days following seven days of dietary exposure to potassium perfluorooctanesulfonate.

Elcombe CR, Elcombe BM, Foster JR, Chang SC, Ehresman DJ, Noker PE, Butenhoff JL.

Toxicology. 2012 Mar 11;293(1-3):30-40. doi: 10.1016/j.tox.2011.12.015. Epub 2012 Jan 8.

PMID:
22239858
4.

Comparative pharmacokinetics of perfluorooctanesulfonate (PFOS) in rats, mice, and monkeys.

Chang SC, Noker PE, Gorman GS, Gibson SJ, Hart JA, Ehresman DJ, Butenhoff JL.

Reprod Toxicol. 2012 Jul;33(4):428-40. doi: 10.1016/j.reprotox.2011.07.002. Epub 2011 Aug 11.

PMID:
21889587
5.

Comparative pharmacokinetics of perfluorohexanesulfonate (PFHxS) in rats, mice, and monkeys.

Sundström M, Chang SC, Noker PE, Gorman GS, Hart JA, Ehresman DJ, Bergman A, Butenhoff JL.

Reprod Toxicol. 2012 Jul;33(4):441-51. doi: 10.1016/j.reprotox.2011.07.004. Epub 2011 Aug 11.

PMID:
21856411
6.

Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination.

Jia L, Gorman GS, Coward LU, Noker PE, McCormick D, Horn TL, Harder JB, Muzzio M, Prabhakar B, Ganesh B, Das Gupta TK, Beattie CW.

Cancer Chemother Pharmacol. 2011 Aug;68(2):513-24. doi: 10.1007/s00280-010-1518-3. Epub 2010 Nov 18.

PMID:
21085965
7.

A novel and rapid LC/MS/MS assay for bioanalysis of Azurin p28 in serum and its pharmacokinetics in mice.

Gorman GS, Coward LU, Freeman L, Noker PE, Beattie CW, Jia L.

J Pharm Biomed Anal. 2010 Dec 1;53(4):991-6. doi: 10.1016/j.jpba.2010.06.006. Epub 2010 Jun 30.

8.

Identifying the safety profile of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in anticipation of a phase I clinical trial in patients with recurrent ovarian cancer.

Matthews K, Noker PE, Tian B, Grimes SD, Fulton R, Schweikart K, Harris R, Aurigemma R, Wang M, Barnes MN, Siegal GP, Hemminki A, Zinn K, Curiel DT, Alvarez RD.

Clin Cancer Res. 2009 Jun 15;15(12):4131-7. doi: 10.1158/1078-0432.CCR-08-3354. Epub 2009 Jun 9.

9.

A comparison of the pharmacokinetics of perfluorobutanesulfonate (PFBS) in rats, monkeys, and humans.

Olsen GW, Chang SC, Noker PE, Gorman GS, Ehresman DJ, Lieder PH, Butenhoff JL.

Toxicology. 2009 Feb 4;256(1-2):65-74. doi: 10.1016/j.tox.2008.11.008. Epub 2008 Nov 19.

PMID:
19059455
10.

Pharmacokinetics and pharmacodynamics of Phor21-betaCG(ala), a lytic peptide conjugate.

Jia L, Noker PE, Piazza GA, Leuschner C, Hansel W, Gorman GS, Coward LU, Tomaszewski J.

J Pharm Pharmacol. 2008 Nov;60(11):1441-8. doi: 10.1211/jpp.60.11.0004.

11.

Comparative pharmacokinetics of perfluorobutyrate in rats, mice, monkeys, and humans and relevance to human exposure via drinking water.

Chang SC, Das K, Ehresman DJ, Ellefson ME, Gorman GS, Hart JA, Noker PE, Tan YM, Lieder PH, Lau C, Olsen GW, Butenhoff JL.

Toxicol Sci. 2008 Jul;104(1):40-53. doi: 10.1093/toxsci/kfn057. Epub 2008 Mar 18.

PMID:
18353799
12.

Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption.

Jia L, Schweikart K, Tomaszewski J, Page JG, Noker PE, Buhrow SA, Reid JM, Ames MM, Munn DH.

Food Chem Toxicol. 2008 Jan;46(1):203-11. Epub 2007 Aug 10.

13.

Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer.

Page JG, Tian B, Schweikart K, Tomaszewski J, Harris R, Broadt T, Polley-Nelson J, Noker PE, Wang M, Makhija S, Aurigemma R, Curiel DT, Alvarez RD.

Am J Obstet Gynecol. 2007 Apr;196(4):389.e1-9; discussion 389.e9-10.

PMID:
17403430
14.

Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate.

Jia L, Coward LC, Kerstner-Wood CD, Cork RL, Gorman GS, Noker PE, Kitada S, Pellecchia M, Reed JC.

Cancer Chemother Pharmacol. 2008 Jan;61(1):63-73. Epub 2007 Mar 14.

PMID:
17356822
15.

Quantitative determination of apogossypol, a pro-apoptotic analog of gossypol, in mouse plasma using LC/MS/MS.

Coward L, Gorman G, Noker P, Kerstner-Wood C, Pellecchia M, Reed JC, Jia L.

J Pharm Biomed Anal. 2006 Nov 16;42(5):581-6. Epub 2006 Jul 21.

PMID:
16859853
16.

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.

Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P.

Clin Cancer Res. 2006 Feb 15;12(4):1317-24. Erratum in: Clin Cancer Res. 2006 Jun 15;12(12):3869. Dosage error in article text.

17.

Interspecies pharmacokinetics and in vitro metabolism of SQ109.

Jia L, Noker PE, Coward L, Gorman GS, Protopopova M, Tomaszewski JE.

Br J Pharmacol. 2006 Mar;147(5):476-85.

18.

Pharmacoproteomic effects of isoniazid, ethambutol, and N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine (SQ109) on Mycobacterium tuberculosis H37Rv.

Jia L, Coward L, Gorman GS, Noker PE, Tomaszewski JE.

J Pharmacol Exp Ther. 2005 Nov;315(2):905-11. Epub 2005 Aug 5.

19.

Simultaneous estimation of pharmacokinetic properties in mice of three anti-tubercular ethambutol analogs obtained from combinatorial lead optimization.

Jia L, Tomaszewski JE, Noker PE, Gorman GS, Glaze E, Protopopova M.

J Pharm Biomed Anal. 2005 Apr 1;37(4):793-9. Epub 2004 Dec 25.

PMID:
15797803
20.

Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug.

Jia L, Tomaszewski JE, Hanrahan C, Coward L, Noker P, Gorman G, Nikonenko B, Protopopova M.

Br J Pharmacol. 2005 Jan;144(1):80-7.

21.

Pharmacokinetics of perfluorooctanoate in cynomolgus monkeys.

Butenhoff JL, Kennedy GL Jr, Hinderliter PM, Lieder PH, Jung R, Hansen KJ, Gorman GS, Noker PE, Thomford PJ.

Toxicol Sci. 2004 Dec;82(2):394-406. Epub 2004 Oct 6.

PMID:
15470233
22.

Toxicity of methylsulfonylmethane in rats.

Horváth K, Noker PE, Somfai-Relle S, Glávits R, Financsek I, Schauss AG.

Food Chem Toxicol. 2002 Oct;40(10):1459-62.

PMID:
12387309
23.

Biodistribution of radiolabeled lipid-DNA complexes and DNA in mice.

Niven R, Pearlman R, Wedeking T, Mackeigan J, Noker P, Simpson-Herren L, Smith JG.

J Pharm Sci. 1998 Nov;87(11):1292-9.

PMID:
9811479
24.

Metabolism of 14C-labelled sucrose esters of stearic acid in rats.

Noker PE, Lin TH, Hill DL, Shigeoka T.

Food Chem Toxicol. 1997 Jun;35(6):589-95.

PMID:
9225017
25.

Dose-related doxorubicin effect in an orthotopic secondary lung cancer screen.

Cowen ME, Howard RB, Noker PE, Zeligman BE, Mulvin DW, Marcell T, Johnston MR.

J Surg Res. 1994 Apr;56(4):295-301.

PMID:
8152221
26.

Purine nucleoside phosphorylase inhibitors: biochemical and pharmacological studies with 9-benzyl-9-deazaguanine and related compounds.

Bennett LL Jr, Allan PW, Noker PE, Rose LM, Niwas S, Montgomery JA, Erion MD.

J Pharmacol Exp Ther. 1993 Aug;266(2):707-14.

PMID:
8355201
27.

Antimitotic agents: structure-activity studies with some pyridine derivatives.

Temple C Jr, Rener GA, Waud WR, Noker PE.

J Med Chem. 1992 Oct 2;35(20):3686-90.

PMID:
1433180
28.

Secondary screening system for preclinical testing of human lung cancer therapies.

Mulvin DW, Howard RB, Mitchell DH, Noker PE, Kruse CA, Chu HD, Bunn PA, Johnston MR.

J Natl Cancer Inst. 1992 Jan 1;84(1):31-7.

PMID:
1310746
29.

Diversity of penetration of anti-cancer agents into solid tumours.

Simpson-Herren L, Noker PE.

Cell Prolif. 1991 Jul;24(4):355-65.

PMID:
1863674
30.

Distribution of adriamycin in mice bearing mammary adenocarcinoma 16/C.

Simpson-Herren L, Noker PE.

Cell Prolif. 1991 May;24(3):241-55.

PMID:
2039801
31.

Effects of the initial chemotherapy on subsequent therapy.

Simpson-Herren L, Noker PE.

Prog Clin Biol Res. 1990;354A:21-9. No abstract available.

PMID:
2247488
32.

Variability of tumor response to chemotherapy. II. Contribution of tumor heterogeneity.

Simpson-Herren L, Noker PE, Wagoner SD.

Cancer Chemother Pharmacol. 1988;22(2):131-6.

PMID:
3409443
33.

Distribution of clomesone in mice.

Noker PE, Hill DL.

Cancer Treat Rep. 1987 Dec;71(12):1135-40.

PMID:
2825990
34.

Variability of tumor response to chemotherapy. I. Contribution of host heterogeneity.

Simpson-Herren L, Noker PE, Wagoner SD.

Cancer Chemother Pharmacol. 1987;20(4):297-304.

PMID:
3690803
35.

Distribution of nitroimidazoles and L-phenylalanine mustard in mammary adenocarcinoma 16/C tumors.

Noker PE, Simpson-Herren L, Wagoner SD.

Cancer Chemother Pharmacol. 1987;20(3):188-92.

PMID:
3677296
36.

Disposition of sucrose octa-isobutyrate in rats, dogs and monkeys.

Noker PE, Kalin JR, McCarthy DJ, el Dareer SM, Chappel CI.

Food Chem Toxicol. 1986 Dec;24(12):1287-93.

PMID:
3100405
37.

Pharmacokinetic and metabolism studies of two novel 1-deaza-7,8-dihydropteridines in mice.

Noker PE, Hill DL, Kalin JR, Temple CG Jr, Montgomery JA.

Drug Metab Dispos. 1985 Nov-Dec;13(6):677-81.

PMID:
2867870
38.

Role of hepatic tetrahydrofolate in the species difference in methanol toxicity.

Black KA, Eells JT, Noker PE, Hawtrey CA, Tephly TR.

Proc Natl Acad Sci U S A. 1985 Jun;82(11):3854-8.

39.

Investigations on the basis for the differential toxicity of hexachlorocyclopentadiene administered to rats by various routes.

El Dareer SM, Noker PE, Tillery KF, Hill DL.

J Toxicol Environ Health. 1983 Aug-Sep;12(2-3):203-11.

PMID:
6655730
40.

Disposition of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-phosphate in mice and dogs.

Noker PE, Duncan GF, El Dareer SM, Hill DL.

Cancer Treat Rep. 1983 May;67(5):445-56.

PMID:
6189605
41.

Disposition of thymidine administered as large doses to rats and mice.

Hill DL, Noker PE, Duncan GF, El Dareer SM.

Cancer Treat Rep. 1981 May-Jun;65(5-6):495-9.

PMID:
7237470
42.

The role of methionine in regulating folate-dependent reactions in isolated rat hepatocytes.

Billings RE, Noker PE, Tephly TR.

Arch Biochem Biophys. 1981 Apr 15;208(1):108-20. No abstract available.

PMID:
6789770
43.

Methanol poisoning and formate oxidation in nitrous oxide-treated rats.

Eells JT, Makar AB, Noker PE, Tephly TR.

J Pharmacol Exp Ther. 1981 Apr;217(1):57-61.

PMID:
7205659
44.

Methanol toxicity: treatment with folic acid and 5-formyl tetrahydrofolic acid.

Noker PE, Eells JT, Tephly TR.

Alcohol Clin Exp Res. 1980 Oct;4(4):378-83.

PMID:
7004236
45.

The role of folates in methanol toxicity.

Noker PE, Tephly TR.

Adv Exp Med Biol. 1980;132:305-15.

PMID:
6968503
46.

Lack of a role for formaldehyde in methanol poisoning in the monkey.

McMartin KE, Martin-Amat G, Noker PE, Tephly TR.

Biochem Pharmacol. 1979 Mar 1;28(5):645-9. No abstract available.

PMID:
109089
47.

Immunological properties of glycolipids from membranes of Acholeplasma laidlawii.

Ryan MD, Noker P, Matz LL.

Infect Immun. 1975 Oct;12(4):799-807.

Supplemental Content

Support Center